Albireo Pharma, Inc. (ALBO): Price and Financial Metrics

Albireo Pharma, Inc. (ALBO)

Today's Latest Price: $33.31 USD

0.77 (2.37%)

Updated Sep 25 4:00pm

Add ALBO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ALBO Stock Summary

  • The ratio of debt to operating expenses for Albireo Pharma Inc is higher than it is for about merely 11.8% of US stocks.
  • With a price/sales ratio of 43.26, Albireo Pharma Inc has a higher such ratio than 95.46% of stocks in our set.
  • As for revenue growth, note that ALBO's revenue has grown 329.11% over the past 12 months; that beats the revenue growth of 97.99% of US companies in our set.
  • Stocks that are quantitatively similar to ALBO, based on their financial statements, market capitalization, and price volatility, are STRO, CLSN, BCRX, FOLD, and EIDX.
  • ALBO's SEC filings can be seen here. And to visit Albireo Pharma Inc's official web site, go to
ALBO Daily Price Range
ALBO 52-Week Price Range

ALBO Stock Price Chart Technical Analysis Charts

ALBO Price/Volume Stats

Current price $33.31 52-week high $49.00
Prev. close $32.54 52-week low $11.26
Day low $32.67 Volume 362,812
Day high $34.32 Avg. volume 198,546
50-day MA $29.79 Dividend yield N/A
200-day MA $24.74 Market Cap 499.35M

Albireo Pharma, Inc. (ALBO) Company Bio

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders. The company is based in Boston, Massachusetts.

ALBO Latest News Stream

Event/Time News Detail
Loading, please wait...

ALBO Latest Social Stream

Loading social stream, please wait...

View Full ALBO Social Stream

Latest ALBO News From Around the Web

Below are the latest news stories about Albireo Pharma Inc that investors may wish to consider to help them evaluate ALBO as an investment opportunity.

A Biotech Pro Bought Up These 3 Stocks

Perceptive Advisors and its hedge fund recently invested a total of $60 million in Athenex, Albireo, and Quotient stock. Two of the stocks are slumping in 2020.

Yahoo | September 19, 2020

Albireo raises $160M in public offering

Albireo Pharma (ALBO) has priced its public offering of 4M common shares at $40.00/share, for expected gross proceeds of $160M.Underwriters' over-allotment is an additional 600K shares.Closing date is September 14.Previously: Albireo launches equity offering of 3M shares (Sept. 8)...

Seeking Alpha | September 10, 2020

Albireo Prices Public Offering of 4,000,000 Shares of Common Stock

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $40.00 per share. Albireo’s gross proceeds from this offering are expected to be $160 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Albireo. The offering is expected to cl...

Yahoo | September 10, 2020

The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Akouos Inc (NASDAQ: AKUS ) Albireo Pharma Inc (NASDAQ: ALB )(announced positive Phase 3 results for odevixibat in a liver disorder called progressive familial intrahepatic cholestasis) Castle Biosciences Inc (NASDAQ: CSTL ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Kura Oncology Inc (NASDAQ: KURA ) Merit Medical Systems, Inc. (NASDAQ: MMSI )(announced sale of manufacturing equipment and associated assets used in its hypotube manufacturing business) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 8) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AEterna Zentaris Inc. (NASDAQ: AEZS )(announced the presentation of data from pediatric study of macimorelin for childhood-o...

Benzinga | September 9, 2020

Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More

The biotech sector remains in focus with regulatory and other pipeline updates.

Yahoo | September 9, 2020

Read More 'ALBO' Stories Here

ALBO Price Returns

1-mo 21.35%
3-mo 13.15%
6-mo 104.48%
1-year 58.09%
3-year 62.96%
5-year 101.88%
YTD 31.04%
2019 3.63%
2018 -4.18%
2017 44.39%
2016 73.82%
2015 -74.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7397 seconds.